Health economics and quality of life issues in heart failure. Satellite symposium. Stockholm, SWE, 1997/08/24.
Congestive heart failure is a severe condition responsible for 1% - 2% of total health expenditure.
In France, three-quarters of the medical cost of congestive heart failure, i.e. FF7 billion, is attributed to 150000 annual hospital admissions.
But new treatments, especially ACE inhibitors and bêta-blockers, have demonstrated, through large controlled trials (SAVE, AIRE, US trials on carvedilol and CIBIS I) that these drugs can reduce mortality and hospitalization.
These results, translated in terms of cost per life year saved, show that they are all very cost effective and could be cost saving, under some conditions.
Mots-clés Pascal : Insuffisance cardiaque, Homme, Coût, Economie santé, France, Europe, Traitement, Chimiothérapie, Efficacité traitement, Inhibiteur angiotensin converting enzyme, Bloquant bêta-adrénergique, Hospitalisation, Morbidité, Mortalité, Exploration, Appareil circulatoire pathologie, Cardiopathie
Mots-clés Pascal anglais : Heart failure, Human, Costs, Health economy, France, Europe, Treatment, Chemotherapy, Treatment efficiency, ACE inhibitor, Beta blocking agent, Hospitalization, Morbidity, Mortality, Exploration, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0084673
Code Inist : 002B12A01. Création : 31/05/1999.